
Stay up-to-date with the latest developments in gene and cell therapy by subscribing to our newsletter.
Featured:
Jul 17 | GenSight Biologics Secures Funding to Advance AAV-Based Gene Therapies for Blinding Eye Diseases read more »
Jul 16 | Genascence’s AAV Gene Therapy for Knee OA Earns FDA RMAT Designation read more »
Jul 14 | Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA read more »
News:
Jul 17 | Rocket Pharma’s RP-A601 Gene Therapy for PKP2-ACM Earns FDA RMAT Designation read more »
Jul 16 | AAVantgarde Bio Gains FDA IND Clearance for Dual AAV Gene Therapy AAVB-039 for Stargardt Disease read more »
Jul 16 | Sarepta Undergoes Major Restructuring, Prioritizes siRNA After Gene Therapy Pipeline Pivot read more »
Jul 16 | Sanofi’s SAR446597 Gene Therapy for Geographic Atrophy Granted FDA Fast Track Designation read more »
Jul 16 | New CMS Model Aims to Unlock Access to Sickle Cell Gene Therapies read more »
Jul 15 | Medera Doses First Patient in AAV Gene Therapy Trial for DMD Cardiomyopathy read more »
Jul 14 | Imugene’s Off-the-Shelf CAR T-Cell Therapy Shows Potent Responses in DLBCL Trial read more »
Jul 14 | MiNK Therapeutics’ iNKT Cell Therap Achieves Complete Remission in Metastatic Testicular Cancer Patient read more »
Jul 11 | FDA Rejects Capricor’s’ Investigational Cell Therapy for DMD Cardiomyopathy read more »
Articles:
Jul 17 | CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients read more »
Jul 17 | A mechanistic basis of fast myofiber vulnerability to neuromuscular diseases read more »
Jul 17 | A vestibulospinal pathway for context-dependent motor control of the mouse tail read more »
Jul 16 | Oral delivery of liquid mRNA therapeutics by an engineered capsule for treatment of preclinical intestinal disease read more »
Jul 16 | AAV-microutrophin gene therapy confers long-term cardioprotection against pharmacologic and exercise-induced injury in dystrophin deficiency read more »
Jul 16 | CAR-T cell therapy and reconstructive oncologic surgery in peripheral solid tumors—A narrative review read more »
Jul 15 | Neo-antigen tumor vaccination depends on CD4-licensing conveyed by adeno-associated virus like particles. read more »
Jul 15 | Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study read more »
Jul 15 | hInGeTox: a human-based in vitro platform to evaluate lentivirus/host interactions that contribute to genotoxicity read more »
Jul 14 | Boosting RNA nanotherapeutics with V-ATPase activating non-inflammatory lipid nanoparticles to treat chronic lung injury read more »
Jul 14 | Bispecific killer cell engager-secreting CAR-T cells redirect natural killer specificity to enhance antitumour responses read more »
Jul 14 | An alternate receptor for adeno-associated viruses read more »
Jul 12 | Chemical circularization of in vitro transcribed RNA for exploring circular mRNA design read more »
Jul 11 | Transabdominal ultrasound guided AAV9-GFP delivery in fetal pigs: a translational and minimally invasive model for in utero fetal gene therapy read more »
Jul 11 | The Responsible Development of Adeno-Associated Virus Gene Therapies read more »
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
